^
Association details:
| Biomarker: | FGFR2 N549K |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | lirafugratinib (RLY-4008) (FGFR2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RLY-4008, a novel precision therapy for FGFR2-driven cancers designed to potently and selectively inhibit FGFR2 and FGFR2 resistance mutations
Published date:
03/10/2021
Excerpt:
...an endometrial cancer model harboring the FGFR2N549K mutation, two mutations that drive clinical progression on current pan-FGFR inhibitors. Notably, treatment of these tumors with RLY-4008 induces rapid regression and restores body weight.
